VCAM1 and acute respiratory distress syndrome: Therefore, NLCs were modified by VCAM-1 monoclonal antibody, which is specifically associated with VCAM-1 receptor overexpressed in pulmonary endothelium under ALI pathological condition, to achieve lung targeting delivery of drugs and while reduce the potential systemic side effects.